Product image of Kardatuxan (Rivaroxaban) supplied by GNH India

Kardatuxan

Active Ingredient:
Rivaroxaban
Origin:
EU

Kardatuxan (Rivaroxaban)

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for the prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism.

GNH India supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across extensive global jurisdictions.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kardatuxan, a direct factor Xa inhibitor, is used in several anticoagulation pathways.

  • Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
  • Deep vein thrombosis (DVT): treats acute clot formation and facilitates resolution.
  • Pulmonary embolism (PE): treats acute embolic events and improves pulmonary circulation.
  • Recurrent DVT/PE prevention: lowers incidence of repeat thrombotic episodes after initial treatment.

How It Works

  • Rivaroxaban selectively binds to the active site of coagulation factor Xa, inhibiting both free and prothrombinase‑complex‑bound forms. By blocking factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing fibrin generation and clot formation. The inhibition is independent of antithrombin III and occurs via oral absorption, achieving rapid onset of anticoagulant effect without the need for routine laboratory monitoring.

Side Effects

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Bruising or minor bleeding: superficial skin or mucosal hemorrhage.
  • Nosebleeds: intermittent epistaxis.
  • Headache: mild to moderate intensity.
  • Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects

  • Severe bleeding: gastrointestinal, intracranial or fatal hemorrhage.
  • Spinal or epidural hematoma: risk with neuraxial procedures.
  • Allergic reactions: rash, angioedema or anaphylaxis.

Precautions & Warnings

Before initiating Kardatuxan, clinicians should consider several safety measures.

  • Assess renal function: adjust dose in patients with impaired clearance.
  • Monitor for bleeding: watch for signs of hemorrhage during therapy.
  • Review concomitant antiplatelet use: evaluate additive bleeding risk.
  • Adjust in hepatic impairment: use caution in moderate liver disease.
  • Avoid in active major bleeding: discontinue if uncontrolled bleeding occurs.
  • Store at room temperature: keep in original container, protect from moisture.

Avoid Interactions

Rivaroxaban interacts with several drug classes that may alter its anticoagulant effect.

Major Interactions (Avoid)

  • Other anticoagulants (e.g., warfarin, heparin): additive anticoagulation increases bleeding risk.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): markedly raise plasma levels.
  • Strong P‑glycoprotein inhibitors (e.g., verapamil, dronedarone): elevate exposure and bleeding potential.

Moderate Interactions (Monitor Closely)

  • Antiplatelet agents (e.g., aspirin, clopidogrel): increase bleeding tendency.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding.
  • Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: heighten risk of mucosal bleeding.

Frequently Asked Questions

Kardatuxan is a prescription anticoagulant containing rivaroxaban. It is approved for preventing stroke and systemic embolism in patients with non‑valvular atrial fibrillation, for treating acute deep vein thrombosis and pulmonary embolism, and for reducing the risk of recurrent DVT or PE after initial therapy.

Rivaroxaban works by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade. By blocking factor Xa, it prevents the conversion of prothrombin to thrombin, which reduces fibrin formation and limits clot development without requiring routine blood‑test monitoring.

The appropriate dose of Kardatuxan is determined by the prescribing clinician based on the specific indication, the patient’s renal and hepatic function, and any concomitant medications. Patients should follow the dosage instructions provided by their healthcare professional.

Safety of rivaroxaban during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Kardatuxan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with vitamin K antagonists such as warfarin, rivaroxaban offers fixed dosing, rapid onset, and does not require routine INR monitoring. Relative to other direct oral anticoagulants, its once‑daily dosing and broad indication profile make it a convenient option, though individual drug‑specific safety and interaction profiles should be considered.

Kardatuxan tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Kardatuxan is taken orally as a whole tablet, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, split, or chew it unless specifically instructed.

The most serious risks include severe or life‑threatening bleeding such as gastrointestinal hemorrhage, intracranial bleeding, and spinal or epidural hematoma. Patients should seek immediate medical attention for signs of unusual bruising, blood in urine or stool, severe headache, or any sudden loss of vision.

Kardatuxan should be avoided in patients with active major bleeding, uncontrolled hypertension, or severe hepatic disease. It is also contraindicated in individuals with known hypersensitivity to rivaroxaban or any of the tablet’s excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Rivaroxaban

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT